Scenic’s platform technology patent receives notice of allowance

Scenic Biotech BV, a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that the patent application covering it’s Cell-Seq technology platform has received notice of allowance from the U.S. Patent And Trademark Office.